FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085834739> ?p ?o ?g. }

• W2085834739 endingPage "613" @default.
• W2085834739 startingPage "605" @default.
• W2085834739 abstract "To report the preliminary results of a Phase I/II study combining radiotherapy and in situ gene therapy (adenovirus/herpes simplex virus thymidine kinase gene/valacyclovir) with or without hormonal therapy in the treatment of prostate cancer.Arm A: low-risk patients (T1-T2a, Gleason score <7, pretreatment PSA <10) were treated with combined radio-gene therapy. A mean dose of 76 Gy was delivered to the prostate with intensity-modulated radiotherapy. Arm B: high-risk patients (T2b-T3, Gleason score >or=7, pretreatment PSA >or=10) were treated with combined radio-gene therapy and hormonal therapy. Hormonal therapy was comprised of a 4-month leuprolide injection and 2-week use of flutamide. Arm C: Stage D1 (positive pelvic lymph node) patients received the same regimen as Arm B, with the additional 45 Gy to the pelvic lymphatics. Treatment-related toxicity was assessed using Cancer Therapy Evaluation Program common toxicity score and Radiation Therapy Oncology Group (RTOG) toxicity score.Thirty patients (13 in Arm A, 14 in Arm B, and 3 in Arm C) completed the trial. Median follow-up was 5.5 months. Eleven patients (37%) developed flu-like symptoms (Cancer Therapy Evaluation Program Grade 1) of fatigue and chills/rigors after gene therapy injection but recovered within 24 h. Four patients (13%) and 2 patients (7%) developed Grade 1 and 2 fever, respectively. There was no patient with weight loss. One patient in Arm B developed Grade 3 elevation in liver enzyme, whereas 11 and 2 patients developed Grade 1 and 2 abnormal liver function tests. There was no Grade 2 or above hematologic toxicity. Three patients had transient rise in creatinine. There was no RTOG Grade 3 or above lower gastrointestinal toxicity. Toxicity levels were as follows: 4 patients (13%), Grade 2; 6 patients (20%), Grade 1; and 20 patients (67%), no toxicity. There was 1 patient with RTOG Grade 3 genitourinary toxicity, 12 patients (40%) with Grade 2, 8 patients (27%) with Grade 1, and 9 patients (30%) with no toxicity. No patient dropped out from the trial or had to withhold treatment because of severe toxicity.This is the first trial of its kind in the field of prostate cancer that aims to expand the therapeutic index of radiotherapy by combining in situ gene therapy. Initial experience has demonstrated the safety of this approach. There is no added toxicity to each therapy used alone. Long-term follow-up and larger cohort studies are warranted to evaluate long-term toxicity and efficacy." @default.
• W2085834739 created "2016-06-24" @default.
• W2085834739 creator A5001835367 @default.
• W2085834739 creator A5012077357 @default.
• W2085834739 creator A5024670184 @default.
• W2085834739 creator A5027840538 @default.
• W2085834739 creator A5029082939 @default.
• W2085834739 creator A5037000397 @default.
• W2085834739 creator A5037470251 @default.
• W2085834739 creator A5041990261 @default.
• W2085834739 creator A5041999677 @default.
• W2085834739 creator A5053448144 @default.
• W2085834739 creator A5053849422 @default.
• W2085834739 creator A5065202811 @default.
• W2085834739 creator A5072634480 @default.
• W2085834739 creator A5073982399 @default.
• W2085834739 creator A5077109761 @default.
• W2085834739 creator A5080482111 @default.
• W2085834739 creator A5082645162 @default.
• W2085834739 creator A5086207046 @default.
• W2085834739 creator A5087750113 @default.
• W2085834739 creator A5088369845 @default.
• W2085834739 date "2001-11-01" @default.
• W2085834739 modified "2023-10-18" @default.
• W2085834739 title "Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer—A preliminary report" @default.
• W2085834739 cites W1414585854 @default.
• W2085834739 cites W1582367115 @default.
• W2085834739 cites W1910139999 @default.
• W2085834739 cites W1968213494 @default.
• W2085834739 cites W1972601062 @default.
• W2085834739 cites W1974190682 @default.
• W2085834739 cites W1989033630 @default.
• W2085834739 cites W2000841137 @default.
• W2085834739 cites W2002483125 @default.
• W2085834739 cites W2009068566 @default.
• W2085834739 cites W2012315955 @default.
• W2085834739 cites W2013474978 @default.
• W2085834739 cites W2018445655 @default.
• W2085834739 cites W2019378587 @default.
• W2085834739 cites W2024356087 @default.
• W2085834739 cites W2040091965 @default.
• W2085834739 cites W2043945205 @default.
• W2085834739 cites W2054125735 @default.
• W2085834739 cites W2062436028 @default.
• W2085834739 cites W2062592944 @default.
• W2085834739 cites W2075718053 @default.
• W2085834739 cites W2083314535 @default.
• W2085834739 cites W2085084790 @default.
• W2085834739 cites W2094315815 @default.
• W2085834739 cites W2095229531 @default.
• W2085834739 cites W2103290459 @default.
• W2085834739 cites W2107475609 @default.
• W2085834739 cites W2114214906 @default.
• W2085834739 cites W2123927174 @default.
• W2085834739 cites W2134009835 @default.
• W2085834739 cites W2137900501 @default.
• W2085834739 cites W2137933052 @default.
• W2085834739 cites W2143575159 @default.
• W2085834739 cites W2145829662 @default.
• W2085834739 cites W2148769388 @default.
• W2085834739 cites W2167919463 @default.
• W2085834739 cites W2175495430 @default.
• W2085834739 cites W2312280006 @default.
• W2085834739 cites W2316095838 @default.
• W2085834739 cites W2334127382 @default.
• W2085834739 cites W4318599446 @default.
• W2085834739 doi "https://doi.org/10.1016/s0360-3016(01)01692-3" @default.
• W2085834739 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11597799" @default.
• W2085834739 hasPublicationYear "2001" @default.
• W2085834739 type Work @default.
• W2085834739 sameAs 2085834739 @default.
• W2085834739 citedByCount "87" @default.
• W2085834739 countsByYear W20858347392012 @default.
• W2085834739 countsByYear W20858347392013 @default.
• W2085834739 countsByYear W20858347392014 @default.
• W2085834739 countsByYear W20858347392015 @default.
• W2085834739 countsByYear W20858347392016 @default.
• W2085834739 countsByYear W20858347392017 @default.
• W2085834739 countsByYear W20858347392021 @default.
• W2085834739 countsByYear W20858347392023 @default.
• W2085834739 crossrefType "journal-article" @default.
• W2085834739 hasAuthorship W2085834739A5001835367 @default.
• W2085834739 hasAuthorship W2085834739A5012077357 @default.
• W2085834739 hasAuthorship W2085834739A5024670184 @default.
• W2085834739 hasAuthorship W2085834739A5027840538 @default.
• W2085834739 hasAuthorship W2085834739A5029082939 @default.
• W2085834739 hasAuthorship W2085834739A5037000397 @default.
• W2085834739 hasAuthorship W2085834739A5037470251 @default.
• W2085834739 hasAuthorship W2085834739A5041990261 @default.
• W2085834739 hasAuthorship W2085834739A5041999677 @default.
• W2085834739 hasAuthorship W2085834739A5053448144 @default.
• W2085834739 hasAuthorship W2085834739A5053849422 @default.
• W2085834739 hasAuthorship W2085834739A5065202811 @default.
• W2085834739 hasAuthorship W2085834739A5072634480 @default.
• W2085834739 hasAuthorship W2085834739A5073982399 @default.
• W2085834739 hasAuthorship W2085834739A5077109761 @default.
• W2085834739 hasAuthorship W2085834739A5080482111 @default.
• W2085834739 hasAuthorship W2085834739A5082645162 @default.

• next